Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7301
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    82.71
    -0.10 (-0.12%)
     
  • Bitcoin CAD

    88,029.83
    -3,213.43 (-3.52%)
     
  • CMC Crypto 200

    1,387.94
    -36.16 (-2.54%)
     
  • GOLD FUTURES

    2,331.50
    -6.90 (-0.30%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,463.50
    -201.00 (-1.14%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,779.42
    -680.66 (-1.77%)
     
  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Can This New Drug Boost Pfizer's Stock?

Can This New Drug Boost Pfizer's Stock?

Pfizer's (NYSE: PFE) nasal spray Zavzpret was given the green light by the Food and Drug Administration earlier this month to treat patients with acute migraine. With this approval, the pharmaceutical company now has an acute migraine treatment in nasal spray form to complement the oral treatment in its portfolio, Nurtec ODT. What could Zavzpret contribute to Pfizer's top line?